Glycolipids and pharmaceutical compositions thereof for use in therapy

Patent metadata

Field	Value
Publication number	US-10428102-B2
Application number	US-201515301264-A
Country	US
Kind code	B2
Filing date	Apr 7, 2015
Priority date	Apr 4, 2014
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

The invention may provide, in part, compounds for use as antiproliferative, chemotherapeutic, antiviral, cell sensitizing or adjuvant agents, and pharmaceutical compositions including the compounds. The compounds may be for use in treating diseases and disorders related to cell proliferation such as cancer, or in treating diseases and disorders which are linked to aberrant control of protein synthesis, such as cancer, viral infection, muscle wasting, autistic spectrum disorders, Alzheimer's disease, Huntingdon's disease and Parkinson's disease.

First claim

The invention claimed is:

1. A compound of Formula Ie:

or a pharmaceutically acceptable salt thereof, for use in medicine,
wherein:
R1 a carbohydrate group;
R2 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
R3 is selected from hydrogen, a C1-C24 alkyl or a C1-C24 derivative of an alkyl group, a C2-C24 alkenyl or a C2-C24 derivative of an alkenyl group, and a C2-C24 alkynyl group or a C2-C24 derivative of an alkynyl group;
X is either absent or is -O-, -NR a -, -S- or -CR a R b -, wherein R a and R b are independently selected from the group consisting of hydrogen and C1-C4 alkyl; and
n is an integer from 1 to 6;

wherein said derivative of alkyl, alkenyl or alkynyl group is composed of said alkyl, alkenyl or alkynyl group wherein one or more of the hydrogen atoms in the hydrocarbon chain of said derivative are replaced with substituent groups selected from hydroxyl, amino, carboxyl, aryl, or heteroaryl groups

2. The compound of claim 1 , wherein the compound has a Formula as follows:

3. The compound of claim 1 , wherein R1 is glucose or galactose.

4. A pharmaceutical composition comprising a compound of claim 1 ,
or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent or excipient.

5. The pharmaceutical composition according to claim 4 , wherein said compound has a Formula as follows:

and said composition further comprises at least one further anti-cancer agent.

6. A nutraceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof,
together with a nutraceutically acceptable carrier, diluent, or excipient.

7. A method for the treatment of a subject having a disease or condition selected from the group consisting of cancer, autistic spectrum disorders, Alzheimer's disease, Parkinson's disease, Huntingdon's disease, muscle wasting and viral infection, the method comprising administering a compound of claim 1 to the subject.

8. The method of claim 7 , wherein the compound is selected from the group consisting of an inhibitor of protein translation, a chemotherapeutic agent, a cell sensitizing agent, an antiproliferative agent, an antiviral agent and an adjuvant.

Assignees

• Univ Nottingham

Inventors

• Bottley Andrew
• Hayes Christopher
• Seymour Graham
• Grabowska Anna
• Clarke Philip

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title